Primary open angle glaucoma is the second most common cause of blindness worldwide. Nitric oxide has recently received particular attention as a potential antiglaucoma agent. In this work, gem-dinitroalkyl benzenes are evaluated for their capability to act as a new class of IOP lowering agents. These derivatives have been endowed with a variety of NO-release capacities and found to relax contracted
原发性开角型青光眼是全世界第二大最常见的失明原因。
一氧化氮作为潜在的抗青光眼剂最近受到了特别的关注。在这项工作中,对宝石-二硝基烷基苯作为新型
IOP降低剂的能力进行了评估。这些衍
生物具有多种NO释放能力,并发现以浓度依赖性方式使收缩的大鼠主动脉条松弛。已经研究了它们在1%剂量的短暂性眼高压兔模型中降低
IOP的活性。降低
IOP的最有效产品是化合物9 – 11和13,其活性与给药后120分钟的Molsidomine相似。化合物使用
卡波姆诱发的青光眼作为
IOP的慢性模型,选择9和13进行评估。它们在开始的24小时内导致
IOP显着降低,并且其活性维持5天以上,显示出类似Molsidomine的特征。